Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annu...( SUNNYVALE Calif. April 3 2008 /-P...)

SUNNYVALE, Calif., April 3, 2008 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced multiple presentations on its novel oncology and autoimmune disease drug candidates at the American Association for Cancer Research (AACR) 2008 Annual Meeting being held April 12-16, 2008, at the San Diego Convention Center in San Diego, CA.

Several presentations relate to the company's histone deacetylase(HDAC) inhibitor, which is now in a multicenter Phase 1 clinical trial, and the use of proprietary biomarkers to predict drug sensitivity. An additional presentation describes the activity of an HDAC-8 selective inhibitor that has demonstrated anti-inflammatory properties in preclinical studies.
The presentations are as follows:

Sunday, April 13, 2008:

-- Session: Histone Deacetylase Inhibitors and Cell Cycle Inhibitors

Poster presentation: The histone deacetylase-8 selective inhibitor

PCI-34051 displays both anti-neoplastic and anti-inflammatory

activities by inducing apoptosis in T-cell derived tumors and blocking

IL-1B secretion in monocytes

Abstract #742: 8:00 a.m. - 12:00 p.m.

Presenter: Sriram Balasubramanian, Ph.D., Pharmacyclics, Inc.

-- Session: Histone Deacetylase Inhibitors and Cell Cycle Inhibitors

Poster presentation: PCI-24781, a novel hydroxamic acid HDAC inhibitor,

raises intracellular levels of reactive oxygen species, induces

apoptosis and inhibits NFkB in leukemia models

Abstract #741: 8:00 a.m. - 12:00 p.m.

Presenter: Shan Gao, University of Texas MD Anderson Cancer Center

Monday, April 14, 2008:

-- Session: Histone Deacetylase and Heat Shock Protein Inhibitors'/>"/>